Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of ergot sterone in preparation of medicaments for treating chronic renal failure

A technology of chronic renal failure and ergosterone, which is applied in the field of medicine, can solve the problems of unsure curative effect, long taking cycle, large toxic and side effects, etc., and achieve the effect of reducing pathological damage and improving renal function

Inactive Publication Date: 2010-07-28
NORTHWEST UNIV(CN)
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although western medicine has a certain curative effect, it has the disadvantages of high toxicity and high recurrence rate. For example, Essite is effective in the early stage, but it will aggravate the condition in the later stage, and the blood creatinine and blood urea nitrogen remain high. eventually develop into uremia
The effect of traditional Chinese medicine treatment is slow, and it takes a month or even a few months to feel whether it is effective. The taking cycle is long. Some patients take the medicine for several years. Long-term taking medicine is very irritating to the stomach. Many patients lose their appetite and lose weight. unsure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0007] Ergosterone is a compound extracted and isolated from the traditional Chinese medicine Polyporus chinensis, which can also be synthesized by chemical synthesis using ergosterol as a substrate.

[0008] The extraction and separation process and organic synthesis process of ergosterone are as follows:

[0009] Ergosterone extraction and separation process: After sliced, dried, and pulverized samples of Polyporus luteum were soaked in about 5 times the volume of 75% ethanol for 24 hours, percolation began to recover methanol and be reused. Concentrate to a brown paste. The paste was dissolved with 75% ethanol, extracted three times with petroleum ether, and the petroleum ether extract was concentrated to obtain a paste. The paste was dissolved in ethanol, mixed with silica gel, put on a 100-200 mesh silica gel column, eluted with petroleum ether-ethyl acetate (10:1), collected fractions, combined, concentrated, finally dissolved in ethyl acetate, and placed , crystallize...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of ergot sterone in the preparation of medicaments for treating chronic renal failure. The ergot sterone has the effects of lowering urea nitrogen and serum creatinine, improving the renal function and reducing the pathological damage of adenine metabolites to the kidney. The invention provides a novel medicament for clinically treating chronic renal failure caused by adenine, aristolochic acid, rhubarb and the like.

Description

technical field [0001] The invention relates to the use of ergosterone in the preparation of medicines for treating chronic renal failure, and belongs to the technical field of medicines. Background technique [0002] The treatment of renal failure has always been a difficult problem in the medical field. According to statistics from the International Society of Nephrology, the annual incidence of chronic renal failure in natural populations is 98-198 / 100 million, and the incidence is higher in economically developed countries. The incidence rates in the United States and Japan are 802 / 1 million and 996 / 100, respectively. Ten thousand. In western countries, renal failure is mainly caused by secondary factors. It has been recognized that diabetes and hypertension are the two primary factors. At least 40% of diabetic patients have kidney disease, and about 50% of hypertensive patients have kidney disease. The number of patients with renal failure in my country is also increa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61P13/12
Inventor 赵英永孙文基谢人明
Owner NORTHWEST UNIV(CN)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products